Maximising the curative potential of chimeric antigen receptor (CAR) T cells will require a multi-pronged approach – improving CAR and cell product design, multivalent targeting and optimal timing of use. Speaking to the limbic at Blood 2018, Professor Stan Riddell said the adoption of uniform ratios of CD4+ and CD8+ T cells in the cell ...
CAR-T cell therapy still on the drawing board over composition & timing
By Mardi Chapman
31 Oct 2018